CTEC Convatec Group PLC
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Convatec Group (LON: CTEC)
›
Convatec Group (LON: CTEC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 10,000 employees.
The shares were at 268.20 GBp on 19 November 2026, up 13.4% over 52 weeks.
At a market capitalisation of 5.12B GBP, it trades at 53.6 times trailing earnings and 15.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, so CTEC is valued in line with them. It pays a dividend yielding 2.05% (it pays out 116% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Convatec Group reports return on equity of 11.5%, an operating margin of 16.3% and revenue up 4.4% year over year.
Its debt exceeds its cash by 1.65B USD, a debt-to-equity ratio of 1.00. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 20 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 312.99 GBp is 16.7% above the current price. The next earnings report is expected on 23 February 2027.